 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY.

Current Price	$26.24
Prev Close	$26.46
Open	$26.75
Dividend Yield	0.00%
50-Day Moving Average	$21.52
Beta	1.59
Avg. Volume	587,686.79
PE Ratio	-6.17

52-Week High	$32.34
52-Week Low	$15.55
Market Capitalization	$1.57B
EPS	-$4.29
Price to Book	4.08
Revenue Per Employee	N/A
Enterprise Value/EBITDA	-2.90

ZNTL Zentalis Pharmaceuticals Inc

About

Feed

Fundamentals

News